Aurinia Pharmaceuticals (AUPH) Misses Q3 EPS by 7c; Initiates Talks with Japan for Voclosporin Phase 1

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. ABBV
3. META
4. SPY
5. FDX
6. IBM
7. MU
8. ACN
9. USO
10. NVDA

Go back to Aurinia Pharmaceuticals (AUPH) Misses Q3 EPS by 7c; Initiates Talks with Japan for Voclosporin Phase 1

Aurinia Reports Third Quarter 2016 Financial Results and Operational Highlights

November 4, 2016 6:55 PM EDT

AURA first global clinical trial in lupus nephritis that meets primary and all secondary endpoints

AURION 24-week results support the use of voclosporin for the treatment of lupus nephritis

Successful completion of EOP2 meeting with FDA

VICTORIA, British Columbia--(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH)(TSX: AUP) (Aurinia or the Company) has released its financial results for the third quarter ended September 30, 2016. Amounts, unless specified otherwise, are expressed in U.S. dollars.

... More